Full-Time

Lead Auditor

Quality Compliance

Updated on 9/12/2026

Integra LifeSciences

Integra LifeSciences

1,001-5,000 employees

Regenerative medicine, surgical devices provider

No salary listed

Rietheim-Weilheim, Germany + 1 more

More locations: Tullamore, Co. Offaly, Ireland

In Person

International travel of up to 50% is required.

Bachelor's, Master's

Category
Manufacturing Quality & Test (1)
Required Skills
GMP
Quality Assurance (QA)
Microbiology
Data Analysis
Google Cloud Platform

Get referred to Integra LifeSciences

See people who can refer or advise you

Requirements
  • Experience serving as a lead auditor for corporate, divisional, site, supplier GMP, GDP, GLP, or GCP audits in multinational medical-device or pharmaceutical manufacturing companies.
  • Related quality or operations GMP experience in a medical-device or pharmaceutical manufacturing site, or an equivalent combination of education and work experience in quality systems, quality assurance, quality control, operations, or a technical management or supervisory function.
  • Experience auditing technical files for conformance with European Union regulations for CE-marked medical devices.
  • Experience conducting supplier or regulatory compliance audits at medical-device or pharmaceutical companies, with the ability to identify and resolve complex quality and compliance issues.
  • Intimate knowledge of 21 CFR Part 820, ISO 13485, the European Union Medical Device Regulation, and Medical Device Single Audit Program country requirements.
  • Experience implementing GMP, GDP, GCP, GLP, and ISO 14971.
  • Experience participating in or leading audits of materials suppliers, manufacturing sites, distribution centers, or laboratories as a lead auditor or site quality assurance/regulatory affairs representative.
  • A bachelor's degree in engineering, sciences, or a relevant technical field is required.
  • Formal auditor certification from a recognized body such as IRCA, ASQ Certified Quality Auditor, BSI, or Exemplar Global.
  • At least 15 years of auditing experience in quality, manufacturing, or engineering, or equivalent education and years of experience.
  • Experience in a United States Food and Drug Administration-controlled environment.
  • Strong collaboration skills and experience working in a matrix environment.
Responsibilities
  • Conduct corporate audits of the Quality Management System as part of the global internal audit program across design, manufacturing, and distribution facilities.
  • Investigate evidence to verify compliance with global Quality Management System policies and standards, global policies and procedures, and regulatory requirements.
  • Prepare formal written reports for the head of the audit program, including audit context, categorized observations, recommendations, site classification, and an executive summary.
  • Identify problematic areas in site and quality-system operations and assist site representatives with improvement recommendations during and after audits.
  • Support inspection readiness through corporate audits, high-risk corrective and preventive action reviews, mock-inspection role-playing, and subject-matter-expert or auditee coaching and feedback.
  • Work with the head of the audit program to improve the efficiency and effectiveness of corporate audit processes and systems while maintaining quality control.
  • Facilitate global implementation of policies at divisional, site, and third-party representative levels through auditing, education, communication, and enforcement.
  • Lead or participate in the required number of corporate audits and work with site quality representatives to finalize reports within standard timelines.
  • Recommend follow-up work or re-audits and participate in continuous-improvement or quality initiatives as a representative of the global quality organization.
  • Provide technical review and support to individuals, working groups, company sites, and approved suppliers.
  • Continue developing personal professional, technical, and auditing expertise.
  • Support a culture of continuous improvement and foster collaboration with cross-functional groups and sites.
  • Provide technical leadership by coaching and teaching team members across functions and geographies.
  • Perform other related duties as expected.
Desired Qualifications
  • Experience working for regulatory agencies such as the United States Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, Therapeutic Goods Administration, Health Canada, Saudi Food and Drug Authority, or Agência Nacional de Vigilância Sanitária, or for notified bodies such as BSI, NSAI, LRQA, or TÜV.
  • Experience in one or more specialized technical areas, including sterilization, microbiology, manufacturing-facility engineering and design, statistical analysis, process validation, regulatory compliance, clinical trials, computer-system validation, quality systems, or data security.
  • Working knowledge of different spoken languages and willingness to travel internationally.
  • A master's degree.
  • Personal experience rolling out and implementing GMP, GDP, GCP, GLP, and ISO 14971.

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue rose 2.4% to $391.9 million, beating expectations.
  • Adjusted EPS jumped to $0.54, and full-year guidance rose to $2.40-$2.50.
  • April 15, 2026 arbitration victory removed ACell earnout liability and reduced legal overhang.

What critics are saying

  • FDA warning letters and the 2025 Boston recall keep disrupting Integra’s core tissue business.
  • The 2026 MediHoney recall and 65 Princeton layoffs signal continuing quality failures and restructuring.
  • If Braintree ramps slowly, SurgiMend delays and Class II recalls can permanently cede share.

What makes Integra LifeSciences unique

  • Integra owns neurosurgery, tissue reconstruction, and ENT niches with specialized device portfolios.
  • Its Braintree, Massachusetts facility restarts SurgiMend production after Boston recall fallout.
  • Stuart Essig returned as CEO in May 2026, tightening execution around remediation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.

Yahoo Finance
May 15th, 2026
Integra LifeSciences beats Q1 expectations, raises full-year EPS guidance to $2.45

Integra LifeSciences reported first-quarter results that beat Wall Street expectations, with revenue of $391.9 million and adjusted EPS of $0.54, surpassing estimates by 2.6% and 33.4%, respectively. The medical device company attributed the performance to stronger tissue reconstruction demand, improved supply execution and operational improvements. CEO Stuart Essig emphasised that quality remediation and operational work enabled more reliable product availability. CFO Lea Knight said increased gross margins were driven by favourable product mix, tariff benefits and reduced remediation costs. The company reaffirmed its full-year revenue guidance of $1.68 billion whilst raising adjusted EPS guidance to $2.45, a 4.3% increase. Operating margin improved to 10.4% from 8.2% year-on-year. Management indicated no plans for divestitures, focusing instead on current product mix and gradual market share recovery.

Yahoo Finance
May 5th, 2026
Integra LifeSciences beats Q1 guidance, raises EPS outlook on tariff gains

Integra LifeSciences reported first-quarter results exceeding guidance, with revenue of $392 million and adjusted earnings per share of $0.54. Revenue increased 2.4% on a reported basis and 1.3% organically, driven by product demand and supply improvements. The company announced leadership changes, with Chairman Stuart Essig resuming the role of President and CEO following Mojdeh Poul's departure. Essig said the decision was mutual and cited differences in strategic topics, though transformation initiatives will continue. Mike McBreen was appointed as the company's first Chief Commercial Officer to elevate commercial priorities. Integra raised its full-year adjusted EPS guidance by $0.10, primarily due to favourable tariff outcomes in the first quarter. CFO Lea Knight noted a $0.02 net tariff benefit but said future tariff assumptions remain uncertain.

Associated Press
May 5th, 2026
Integra LifeSciences Q1 revenues rise 2.4% to $391.9M, raises full-year EPS guidance

Integra LifeSciences reported first quarter 2026 revenues of $391.9 million, up 2.4% on a reported basis and 1.3% organically compared to the prior year. The medical technology company posted adjusted earnings per diluted share of $0.54, up from $0.41 in the prior year. The company reaffirmed full-year 2026 revenue guidance of $1.662 billion to $1.702 billion whilst raising its adjusted earnings per share guidance to $2.40 to $2.50, up from the previous range of $2.30 to $2.40. Adjusted EBITDA for the quarter was $76.2 million, representing 19.4% of revenue, compared to $63.6 million or 16.6% in the prior year. The company generated $9.8 million in operating cash flow during the quarter, with net debt standing at $1.6 billion.